New Jersey Senate Bill S1320

New Jersey 2026-2027 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26

Caption

Requires health insurers to provide coverage for treatment of tick-borne diseases.

Impact

If enacted, S1320 would significantly impact the healthcare landscape concerning insurance coverage for tick-borne diseases. This implies that health plans would be obliged to cover treatments that are considered medically necessary, which could increase awareness and treatment options for individuals suffering from such diseases. Moreover, it underlines the importance of accessible healthcare for conditions that may not yet be fully recognized as needing extensive treatment protocols by existing insurance guidelines.

Summary

Senate Bill S1320 aims to require health insurers in New Jersey to provide coverage for expenses related to the treatment of tick-borne diseases. This includes long-term antibiotic therapy and ongoing testing, which are deemed medically necessary by a patient's physician. The bill outlines definitions of tick-borne diseases and long-term antibiotic therapies, emphasizing that treatment should not be denied based on characterizations of being experimental or investigational.

Contention

The bill's language indicates that treatment should be recognized even if it involves off-label drug use as long as it meets certain clinical standards. This provision might raise concerns among some insurers about the rising costs associated with providing extensive coverage for potentially lengthy and expensive treatments. Critics may argue that such mandates could lead to increased premiums for all insured individuals, stressing the need for a balance between sufficient coverage and insurance viability.